OBJECTIVE: The expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 (pp-GalNAc-T12) was studied in 3 normal human tissues (stomach, small intestine and colon), 3 stomach and 6 colon cancer cell lines, as well as in the resected cancer tissues and normal tissues (control) from 19 patients with colorectal cancer. METHODS: Marathon Ready cDNAs were used as the templates of normal tissues. mRNA was extracted from the cell lines and resected tissues, and reverse-transcribed to cDNA. The expression of pp-GalNAc-T12 was determined with a real-time polymerase chain reaction (PCR). RESULTS: It was found that the expression of pp-GalNAc-T12 was strong in 3 normal tissues, weak or negligible in 9 cancer cell lines, and down-regulated in all of the colorectal cancer tissues as compared with normal control samples. Moreover, the expression of pp-GalNAc-T12 tended to inversely correlate with the TNM stage, and statistically was much lower in the samples with metastasis than in those without. However, the expression in the tissues did not correlate with the concentration of serum CA 19-9 routinely applied in the diagnosis and assessment of prognosis in patients with colonic cancers. CONCLUSION: the expression of pp-GalNAc-T12 seems to be a negative marker especially of metastatic gastric and colorectal cancer.
OBJECTIVE: The expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 (pp-GalNAc-T12) was studied in 3 normal human tissues (stomach, small intestine and colon), 3 stomach and 6 colon cancer cell lines, as well as in the resected cancer tissues and normal tissues (control) from 19 patients with colorectal cancer. METHODS: Marathon Ready cDNAs were used as the templates of normal tissues. mRNA was extracted from the cell lines and resected tissues, and reverse-transcribed to cDNA. The expression of pp-GalNAc-T12 was determined with a real-time polymerase chain reaction (PCR). RESULTS: It was found that the expression of pp-GalNAc-T12 was strong in 3 normal tissues, weak or negligible in 9 cancer cell lines, and down-regulated in all of the colorectal cancer tissues as compared with normal control samples. Moreover, the expression of pp-GalNAc-T12 tended to inversely correlate with the TNM stage, and statistically was much lower in the samples with metastasis than in those without. However, the expression in the tissues did not correlate with the concentration of serum CA 19-9 routinely applied in the diagnosis and assessment of prognosis in patients with colonic cancers. CONCLUSION: the expression of pp-GalNAc-T12 seems to be a negative marker especially of metastatic gastric and colorectal cancer.
Authors: Thomas A Gerken; Oliver Jamison; Cynthia L Perrine; Jeremy C Collette; Helen Moinova; Lakshmeswari Ravi; Sanford D Markowitz; Wei Shen; Himatkumar Patel; Lawrence A Tabak Journal: J Biol Chem Date: 2011-02-24 Impact factor: 5.157
Authors: Miguel C Lucena; Patricia Carvalho-Cruz; Joana L Donadio; Isadora A Oliveira; Rafaela M de Queiroz; Monica M Marinho-Carvalho; Mauro Sola-Penna; Iron F de Paula; Katia C Gondim; Mark E McComb; Catherine E Costello; Stephen A Whelan; Adriane R Todeschini; Wagner B Dias Journal: J Biol Chem Date: 2016-04-18 Impact factor: 5.157
Authors: Earnest James Paul Daniel; Matilde Las Rivas; Erandi Lira-Navarrete; Ana García-García; Ramon Hurtado-Guerrero; Henrik Clausen; Thomas A Gerken Journal: Glycobiology Date: 2020-10-21 Impact factor: 4.313
Authors: Tongzhong Ju; Rajindra P Aryal; Matthew R Kudelka; Yingchun Wang; Richard D Cummings Journal: Cancer Biomark Date: 2014-01-01 Impact factor: 4.388
Authors: Daniel R Evans; Srividya Venkitachalam; Leslie Revoredo; Amanda T Dohey; Erica Clarke; Julia J Pennell; Amy E Powell; Erina Quinn; Lakshmeswari Ravi; Thomas A Gerken; Jane S Green; Michael O Woods; Kishore Guda Journal: Hum Mutat Date: 2018-05-28 Impact factor: 4.878
Authors: Andréia Vasconcelos-Dos-Santos; Isadora A Oliveira; Miguel Clodomiro Lucena; Natalia Rodrigues Mantuano; Stephen A Whelan; Wagner Barbosa Dias; Adriane Regina Todeschini Journal: Front Oncol Date: 2015-06-25 Impact factor: 6.244
Authors: Bianca T Hofmann; Laura Schlüter; Philip Lange; Baris Mercanoglu; Florian Ewald; Aljonna Fölster; Aeint-Steffen Picksak; Sönke Harder; Alexander T El Gammal; Katharina Grupp; Cenap Güngör; Astrid Drenckhan; Hartmut Schlüter; Christoph Wagener; Jakob R Izbicki; Manfred Jücker; Maximilian Bockhorn; Gerrit Wolters-Eisfeld Journal: Mol Cancer Date: 2015-05-29 Impact factor: 27.401
Authors: Yanran He; Karin Schreiber; Steven P Wolf; Frank Wen; Catharina Steentoft; Jonathan Zerweck; Madeline Steiner; Preeti Sharma; H Michael Shepard; Avery Posey; Carl H June; Ulla Mandel; Henrik Clausen; Matthias Leisegang; Stephen C Meredith; David M Kranz; Hans Schreiber Journal: JCI Insight Date: 2019-11-01